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ABSTRACT 
Objectives: In present study, an attempt was made to design sustained-release tablets containing Didanosine using natural gums like Xanthan gum, 
Guar gum and Karaya gum. Methods: The sustained-release tablets containing Didanosine prepared by using natural gums by wet granulation 
method. Influence of natural polymer on Didanosine was studied. The prepared tablets were selected for DSC and FTIR studies.  
Results and Discussions: The tablets were selected for DSC and FTIR studies did not show any chemical interaction between drug and polymer. The 
prepared formulations were evaluated for Hardness, Thickness, Friability, Weight variation, drug content estimation, Swelling index, in-vitro drug 
release are within the acceptable standard. In-vitro release profile was check for 8 hrs to evaluate the SR matrix tablet of Didanosine. The optimized 
tablets were carried out according to ICH guidelines at 40 ± 20 C/ 75 ± 5% RH for three months. All the prepared tablets were stable at room 
temperature. The values of pre-compression parameters of prepared granules were evaluated the results were within prescribed limits and 
indicated good free flowing property. The prepared tablets were subjected to all the quality control tests they were within the official 
pharmacopoeial limits. Friability is less than 1%, indicated that tablets had a good mechanical resistance. Weight variation test revealed that the 
tablets were within the range of pharmacopoeial limit. Thickness, hardness and drug content were within the range of pharmacopoeial limit. The 
evaluation parameters were within acceptable range for all the formulations. The in-vitro release of Didanosine was conducted for 8 hrs. The 
optimized formulations WGX3, WGG5 and WGK9 sustained the release up to 8hr. Hence Didanosine along with Xanthan gum, Guar gum and Karaya 
Gum could be used to prepare sustained released matrix tablets. The in-vitro release obeyed zero order kinetics with mechanism of release was 
erosion followed by non-fickian diffusion.  
Conclusion: Among all the formulations WGK9 is the best shows excellent release around 99% after 8 hrs. The prepared matrix tablets of 
Didanosine were stable. So, it may be concluded that sustained release matrix tablets would improve the patient compliance and bioavailability may 
be improved. 
Keywords: Didanosine, Xanthan gum, Guar gum and Karaya gum. 
INTRODUCTION 
In recent years the basic aim has been designing of drug products to 
reduce the frequency of dosing by modifying rate of the drug release 
from the formulation [1]. Regular research has been carried in this 
field for the use of naturally occurring biocompatible polymeric 
material in designing the dosage form for oral controlled release         
administration [2, 3]. Hydrophilic swellable polymers are widely 
used to control the release of the drugs from polymer matrix 
formulations [4, 5]. Gums of natural sources are biodegradable and 
nontoxic, which hydrate and swell on contact with aqueous media; 
and these have been used for the preparation of single use dosage 
forms [6]. 
Drug release from hydrophilic matrix tablets are sustained by 
formation of hydrated viscous layer around the tablet which acts as 
a barrier to drug release by opposing penetration of water in to the 
tablet and also the movement of dissolved solute out of matrix 
tablet[7]. Hydrophilic polymers have attracted considerable 
attention in recent years as sustained controlled release devices for 
the delivery of water soluble and water insoluble agents. Their 
characteristics and their ability to hydrate and form a gel layer are 
well known and essential to sustain and control drug release from 
matrices [8]. The hydrated gel layer thickness determines the 
diffusion path of the drug molecules through the polymer mass in to 
dissolution medium [9]. A number of natural and number of 
polysaccharides, such as xanthan gum, guar gum and Karaya gum, 
have been showed to be useful for controlled release due to their 
hydrophilic properties [10]. 
AIDS is considered to be an epidemic according to estimates from 
the UNAIDS/WHO AIDS Epidemic update, December 2005, 38.0 
million adults and 2.3 million were living with human 
immunodeficiency virus (HIV) at the end of 2005. The annual 
number AIDS patients can be expected to increase for many years to 
come, unless more effective and patient compliant antiretroviral 
medications are available at affordable prices[11]. The major 
drawbacks of antiretroviral drugs for the treatment of AIDS are their 
adverse side effects during long-term therapy, poor patient 
compliance and huge cost of the therapy [12, 13]. Didanosine (NRTI) 
is a potent antiviral agent used in the treatment of AIDS. 
Conventional formulations of NRTI are administered multiple times 
a day depending on the dose (100 mg to 400 mg) due to its short 
half-life (t1/2: 1.5±0.4 hrs)[14-16]. Treatment of AIDS using 
conventional formulations of NRTI is found to have many drawbacks 
such as adverse side effects due to accumulation of drug in multi-
dose therapy [17, 18]. Poor patient compliance [19] and high cost. 
In present study, an attempt was made to design sustained-release 
tablets containing Didanosine using Xanthan gum, Guar gum and 
Karaya gum. by wet granulation method. Formulation of Didanosine 
matrix tablet was prepared by the polymer. Influence of natural 
polymer on Didanosine was studied. 
MATERIALS AND METHODS 
Didanosine was obtained as a gift sample from Aurobindo Pharma. 
Hyderabad. Guar Gum obtained from SD Fine Chemicals. Mumbai. 
Xanthan gum, Karaya gum purchased from ANL laboratories 
Warangal. All other chemicals used were of analytical grade. 
Preparation of sustained release matrix tablets of Didanosine 
Wet granulation method: Matrix tablet containing 100mg of 
Didanosine were prepared by wet granulation technique. The 
composition of each tablet is shown in table. All the components 
were screened and then thoroughly mixed in a bottle using tumbling 
 Vol 7, Suppl 1, 2014                                                                                                                                                                                                        ISSN - 0974-2441                                                                                                                                                                                                 
Rao et al. 
Asian J Pharm Clin Res, Vol 7, Suppl 1, 2014, 38-44 
39 
 
method for a period of 15 min. The powder mix was granulated with 
isopropyl alcohol. The wet mass was passed through # 16 and the 
granules were dried at 500C for 2 hrs. in a hot air oven. The dried 
granules were passed through # 20 and lubricated with magnesium 
stearate by further blending for 3 min and finally talc was added to 
the blend. Compression was done on 12 station Rimek tablet 
compression machine (M/s Karnawati Engg. Ltd. Ahmadabad) using 
8 mm punches. The weight of the tablets was kept constant for all 
the formulations (Table 1). 
Table 1: Composition of Didanosine sustained release matrix tablets by wet granulation   method (weight in mg) 
Ingredients WGX1 WGX2 WGX3 WGX4 WGG5 WGG6 WGG7 WGG8 WGK9 WGK10 WGK11 
Didanosine 100 100 100 100 100 100 100 100 100 100 100 
XG 80 100 120 140 - - - - - - - 
GG - - - - 80 100 120 140 - - - 
KG - - - - - - - - 100 150 200 
MCC 20 20 20 20 20 20 20 20 140 90 40 
IPA q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Talc 2 2 2 2 2 2 2 2 2 2 2 
Mg stae 3 3 3 3 3 3 3 3 3 3 3 
PVP K30 5 5 5 5 5 5 5 5 5 5 5 
Acacia 20 20 20 20 20 20 20 20 20 20 20 
Lactose 120 100 80 60 120 100 80 60 - - - 
TOTAL WT 350 350 350 350 350 350 350 350 350 350 350 
XG=Xanthan gum, GG=Guar gum, KG=Karaya gum, IPA=Isopropyl alcohol, MCC=Microcrystalline cellulose, Mg Stae=Magnesium stearate 
Evaluation of granules 
Angle of Repose: The angle of repose of granules was determined 
by the funnel method. The accurately weighed physical mixture was 
taken in a funnel. The height of the funnel was adjusted in such a 
manner that the tip of the funnel just touched the apex of the heap of 
the granules. The granules were allowed to flow through the funnel 
freely onto the surface. The diameter of the granules cone measured 
and angle of repose was calculated using the following equation. 
                             Tan θ = h/r 
Where, h and r are the height and radius of the granules cone, θ is 
the angle of repose. 
Loose Bulk Density (LBD): An accurately weighed granules from 
each formulation was lightly shaken to break any agglomerates 
formed and it was introduced in to a measuring cylinder. The 
volume occupied by the powders was measured which gave bulk 
volume. The loose bulk density (LBD) of granules was determined 
using the following formula. 
Loose bulk density = Total weight of granules / Total volume of 
granules 
Tapped bulk density (TBD): An accurately weighed granules from 
each formulation was lightly shaken to break any agglomerates 
formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume 
was noted which gave the tapped volume. The TBD of granules was 
determined by the following formula. 
Tapped bulk density= Total weight of granules / Tapped volume 
Carr’s Compressibility Index: It is a simple index that can be 
determined on small quantities of granules. In theory, the less 
compressible a material the more flowable it is. The compressibility 
index of the granules was determined using following formula [20]. 
Carr’s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Where, TBD = Tapped Bulk Density 
LBD = Loose Bulk Density 
Hausner’s Ratio: It is the ratio of tapped density and bulk density. 
Hausner found that this ratio was related to interparticle friction 
and, as such, could be used to predict granules flow properties [21]. 
Generally a value less than 1.25 indicates good flow properties, 
which is equivalent to 20% of Carr’s index. And greater than 1.5 
indicates that poor flow, in between these values passable. 
Evaluation of tablets 
The prepared tablets were evaluated for weight variation, tablet 
hardness, friability, and thickness, content uniformity, and in-vitro 
drug release. 
Weight variation: The weight of the tablet being made was   
routinely determined to ensure   that a tablet contains the proper 
amount of drug. The USP weight variation test is done by weighing 
20  tablets  individually,  calculating  the average  weight  and  
comparing  the  individual weights  to  the  average. The  tablets  met  
the  USP  specification  that  not  more  than  2 tablets are outside the 
percentage limits and no tablet differs by more than 2 times the 
percentage limit. USP official limits. 
Tablet hardness: The  resistance  of  tablets  to  shipping  or  
breakage  under  conditions  of  storage, transportation and handling 
before  usage  depends  on  its  hardness.  The hardness of each batch 
of tablet was checked by using Pfizer hardness tester. The hardness 
was measured in terms of kg/cm2.  Six tablets were chosen randomly 
and tested for hardness. The average hardness of six determinations 
was recorded. 
Friability: Friability determines the resistance of tablets to shipping 
or breakage under conditions of storage, transportation and 
handling before usage. Friability generally refers to loss in weight of 
tablets in the containers due to removal of fines from the tablet 
surface. Friability generally reflects poor cohesion of tablet 
ingredients. If there is any chipping, capping, cracking or breaking of 
tablet; then the batch should be rejected. 
Method: 20  tablets  were  weighed  and  the  initial  weight  of  these  
tablets  was  recorded  and placed  in  Roche  friabilator  and  rotated 
at  the  speed  of 25  rpm  for 100  revolutions. Then  tablets  were  
removed  from  the  friabilator,  dusted  off  the  fines  and  again 
weighed and the weight was recorded. 
F=W1 /W2×100         
Where: F = Friability 
W1= weight of the tablet before test. 
W2= weight of the tablet after test 
Dimensions: The dimensions of the tablets are thickness and 
diameter. The tablets should have uniform thickness and diameter. 
The manufacturer normally states these. Thickness and diameter of 
a tablet were measured using vernier callipers. These values were 
checked and used to adjust the initial stages of compression. 
Drug content studies: The study to find out the actual drug content 
in different formulation against the standard drug was performed by 
taking the ratio of absorbance for the sample and the pure drug. Five 
tablets were taken and amount of drug present in each tablet was 
determined and the tablets were crushed in a Pestle mortar into 
powder which was transferred as amount equivalent to 40mg to 
100ml standard flask. The powder was dissolving in 7.4 pH buffer 
and made up to volume with 7.4 pH buffer solution and the sample 
was mixed thoroughly and filtered through Whatmann filter paper.  
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The filtered solution was diluted suitably and analyzed for drug 
content by UV-VIS Spectrophotometer at wavelength 200nm and 
400nm. Percentage of drug content was determined by comparing of 
standard with the prepared formulations. 
Determination of swelling and erosion index: The swelling index 
of all the tablet formulations was studied. The extent of swelling was 
measured in terms of percent weight gain by the tablet. One tablet 
from each formulation was kept in a petri dish containing 15 ml of 
phosphate buffer pH 7.4. At the end of 1hr, the tablet was 
withdrawn, wiped with tissue paper, and weighed. Then for every 
1hrs, weights of the tablet were noted, and the process was 
continued till the end of 6 h. The percent weight gain of the tablets 
was calculated  
To determine matrix erosion, swollen tablets were placed in a 
vacuum oven at 400C and after 48 hrs, tablets were removed and 
weighed. Swelling (%) and erosion (%)was  calculated  according  to  
the  following  formula,  where  S  is  the  weight  of  the matrix 
tablets after swelling; R is the weight of the eroded tablet and T is 
the initial weight of the matrix  tablets. 
Swelling index= (S-T)/T×100 
% Erosion = (T-R)/T×100 
In-vitro Dissolution studies: In-vitro dissolution study of 
Didanosine was carried using Electrolab TDT-08L USP dissolution 
test apparatus. The details are given as below. 
LABINDIA USP dissolution test apparatus 
Medium        : pH 7.4 buffer solution  
RPM             : 50 
Time             : 12 hrs 
Temp            : 370 C ± 50 C            
Volume        : 900ml 
Wave length : 249 nm 
Procedure: Tablet  was  introduced  into  dissolution  test  
apparatus  and  the  apparatus  was  set  at 50 rpm.  5  ml  of  sample  
was  withdrawn  at  every  1hr  interval  and  replaced  by  the 
respective  buffer  solutions.  Samples withdrawn were analyzed by 
UV spectrophotometer at 249 nm in 7.4 pH for estimation of amount 
of drug released using buffer solution as blank. 
Release kinetics: Data obtained from in-vitro release studied was 
evaluated to check the goodness of fit to various kinetics equations 
for quantifying the phenomena controlling the release from 
microspheres. The kinetic models used were zero order, first order, 
and Higuchi and Korsmeyer-peppas model. The goodness of fit was 
evaluated using the correlation coefficient values (R2). 
Interpretation of diffusion release mechanisms from tablets  
N Mechanism 
0.5 Fickian diffusion 
0.5<n<1 Non- fickian diffusion 
1 Class II transport 
>1.0 Class II transport 
 
Characterization of Didanosine tablets 
FTIR Studies: IR spectra for drug Didanosine, formulation with 
xanthan gum, formulation with guar gum and formulation with 
karaya gum were recorded in a Fourier transform infrared (FTIR) 
spectrophotometer (FTIR 1615, Perkin Elmer, USA) with KBr pellets. 
DSC Studies: DSC scan of about 5mg, accurately weighed drug 
Didanosine and formulation with xanthan gum, formulation with 
guar gum and formulation with karaya gum were performed by 
using an automatic thermal analyzer system. (DSC60 Shimadzu 
Corporation, Japan) Sealed and perforated aluminum pans were 
used in the experiments for all the samples. Temperature 
calibrations were performed using Indium as standard. An empty 
pan sealed in the same way as for the sample was used as a 
reference. The entire samples were run at a scanning rate of 
100C/min from 50-3000C. 
Stability studies: Optimized Didanosine matrix tablets were 
selected for stability studies [7]. The stability studies was carried out 
according to ICH guidelines at 40 ± 20C/75 ± 5% RH for three months 
by storing the samples in (Labcare, Mumbai) stability chamber.  
Purpose of Stability Testing 
To ensure the efficacy, safety and quality of active ingredient(s) and 
formulation. 
To establish shelf life or expiry date and to support label claim. 
It provides for a rapid means of quality control. 
RESULTS AND DISCUSSION: 
Granulation is the key process in the production of many dosage 
forms. To ensure good content uniformity and avoid flow related 
inter tablet weight variation problems. Wet granulation is preferred 
in routine commercial production. Wet granulation was thus used in 
the present study. 
The values of pre-compression parameters of prepared granules 
were evaluated the results were within prescribed limits and 
indicated good free flowing property. The results of pre-
compression parameters were given in Table 2. 
 












Compresssibity Index (%) 
(±SD), n=3 
Angle of repose (⁰) 
(±SD), n=3 
WGX1 0.56  ± 0.026 0.59 ± 0.015 1.05  ±  0.054 
 
5.1 ± 0.001 30.80 ± 0.006 
WGX2 0.45 ± 0.054 0.48 ± 0.036 1.07 ± 0.058 6.2 ± 0.020 30.41 ±  0.012 
WGX3 0.45 ± 0.153 0.50 ± 0.054 1.11 ± 0.015 10.0 ± 0.010 28.55 ±  0.026 
WGX4 0.50 ± 0.041 0.53 ± 0.084 1.06 ± 0.020 5.70 ± .020 30.50 ± 0.076 
WGG5 0.50 ± 0.016 0.56  ± 0.054 1.12 ± 0.032 10.7 ± 0.041 27.11  ± 0.113 
WGG6 0.48 ± 0.028 0.50 ±  0.026 1.04 ± 0.018 4.0 ± 0.051 30.30  ± 0.006 
WGG7 0.45 ±  0.023 0.50  ± 0.027 1.11 ±0.008 10.0 ± 0.020 26.41  ± 0.017 
WGG8 0.50 ± 0.058 0.56 ±  0.058 1.12 ± 0.002 10.7 ±  0.021 29.60  ± 0.115 
WGK9 0.50 ± 0.016 0.58 ± 0.012 1.10  ±  0.052 
 
13.7 ± 0.014 29.70 ± 0.006 
WGK10 0.49 ± 0.041 0.56 ± 0.036 1.09 ± 0.021 12.5 ± 0.040 28.51 ±  0.012 
WGK11 0.45 ± 0.150 0.52 ± 0.054 1.10 ± 0.014 13.4 ± 0.101 29.45 ±  0.026 
FC=Formulation code 
The prepared tablets were subjected to all the quality control tests 
which showed    (Table 3) that they were within the official 
pharmacopoeial limits. Friability is less than 1%, indicated that 
tablets had a good mechanical resistance. Weight variation test 
revealed that the tablets were within the range of pharmacopoeial 
limit. Thickness of the tablets was ranges from 4.24 to 5.08 mm. The 
evaluation parameters were within acceptable range for all the 
formulations. The drug content of the tablets was ranges from 96 % 
to 99%. The results of hardness, friability, weight variation, 
thickness and drug content were given in Table 3. 
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Hardness (±SD), n=3 Drug content (±SD), n=3 
WGX1 4.24  ± 0.402 351.23 ± 0.250 0.28 ± 0.245 6.2 ± 0.201 96 ± 0.48 
WGX2 4.50 ± 0.204 350.82 ± 0.361 0.56 ± 0.302 6.0 ± 0.045 98 ± 0.45 
WGX3 5.02 ± 0.307 352.24 ± 0.503 0.28 ± 0.450 6.3 ± 0.420 99 ± 0.54 
WGX4 4.60 ± 0.415 351.46 ± 0.452 0.57 ± 0.105 5.9 ± 0.325 97 ± 0.85 
WGG5 4.80 ± 0.350 350.26 ± 0.211 0.56 ± 0.450 5.8 ± 0.220 99 ± 0.24 
WGG6 4.72 ± 0.409 351.51 ± 0.320 0.30 ± 0.320 6.1 ± 0.450 98 ± 0.36 
WGG7 4.95 ± 0.305 350.90 ± 0.251 0.58 ± 0.452 6.2 ± 0.500 96 ± 0.25 
WGG8 5.05 ± 0.405 353.15 ± 0.530 0.48 ± 0.040 6.0 ± 0.105 97 ± 0.50 
WGK9 5.01 ± 0.025 351.01 ± 0.023 0.25 ± 0.026 6.0 ± 0.029 96 ± 1.25 
WGK10 5.04 ± 0.032 350.02 ± 0.032 0.32 ± 0.029 6.1 ± 0.015 97 ± 1.30 
WGK11 5.01 ± 0.041 352.05 ± 0.035 0.36 ± 0.035 6.0 ± 0.040 99 ± 1.50 
FC=Formulation code 
The swelling study of prepared Didanosine tablets was performed in 
phosphate buffer pH 7.4 and the results are presented as percentage 
weight change with respect to time. The swelling behavior is an 
important property for uniform and sustained release of drugs. The 
swelling behavior depends upon the nature of polymer, 
concentration of polymer and pH of the medium. The highest 
swelling observed in the formulation with karaya gum, as shown in 
Table 4. The least swelling is observed in formulation with xanthan 
gum. Because weight gain by tablet was increased proportionally 
with rate of hydration. Later on, it decreases gradually due to 
dissolution of outer most gel layer of the tablet in dissolution 
medium from the swelling data it is concluded that swelling is the 
dominant mechanism of drug release in karaya gum, while in case of 
xanthan gum initially swelling and then erosion is the mechanism of 
drug release. 
Table 4: Swelling Index of Xanthan Gum, Guar Gum and Karaya Gum of Didanosine matrix tablets 
Time (hrs) WGX1 WGX2 WGX3 WGX4 WGG5 WGG6 WGG7 WGG8 WGK9 WGK10 WGK11 
0hr 0 0 0 0 0 0 0 0 0 0 0 
1hr 65.25 68.4 70 74.2 69.2 75.8 78.7 80 65.2 71.1 72 
2hr 88.66 90.2 92.02 97.4 78.5 80.5 83.1 87.2 75.8 86.3 92.5 
3hr 95.4 98.2 99.7 104.5 88.8 90.2 95.8 98.14 95.1 98.8 102.3 
4hr 98.5 104.2 106.5 110.14 101.5 105.14 108.2 112.1 106.8 112.3 120.4 
5hr 101.1 109.1 111.5 115 106.2 110.2 112.8 120.2 115.1 120.5 129.8 
6hr 106.7 114.5 116.2 119.1 110.2 115.1 119.4 124.1 125.4 125.3 135.2 
7hr 115.1 118.3 121.1 123.1 116.1 119.8 123.4 128.6 135.2 138.1 142 
8hr 119.24 122.1 125.6 129.2 120.5 125.1 128.3 131 150.2 152.3 155 
In-vitro dissolution studies of all the formulations of sustained 
release tablets of Didanosine were carried out in pH 7.4 phosphate 
buffers for 8 hrs respectively. The study was performed for 8 hrs, 
and percentage drug release was calculated at 1 hrs time intervals. 
The dissolution profile of Didanosine tablets (350mg) containing 
Xanthan gum (WGX1, WGX2, WGX3, WGX4) showed a maximum 
drug release 80<% within 8 hrs as and  among all the formulations 
WGX3 showed best release of 96% at 8hrs as shown in Fig 1. The 
Didanosine tablets (350mg) containing Guar gum (WGG5, WGG6, 
WGG7, WGG8) showed a maximum drug release 75<% within 8 hrs 
and  among all the formulations WGG5 showed best release of 95% 
at 8 hrs, as shown in Fig 2. The Didanosine tablets (350mg) 
containing Karaya Gum (WGK9, WGK10, WGK11)  showed a 
maximum drug release 80<% within 8 hrs and  among all the 
formulations WGK9 showed best release of 99% at 8hrs as shown in 
Fig 3.  
 
Fig 1: In- vitro release profile of formulation WGX-1 to WGX-4. 
 
 
Fig 2: In- vitro release profile of formulation WGG-5 to WGG-8. 
 
Fig 3: In- vitro release profile of formulation WGK-9 to WGK-11. 
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The values of release parameters, n and k, are incersely related. A 
higher value of k may suggest burst drug release from the matrix. 
According to the criteria for release kinetics from swellable systems, 
a value of release exponent, n= 0.45, 0.45<n<0.89 and 0.89<n<1.0 
indicates Fickian (case I) diffusion, non-Fickian (anamalous) 
diffusion and zero order (case II) transport, respectively. A result 
reveals that all formulations follow zero order kinetics as correlation 
coefficient (r2) values are higher than that of first order release 
kinetics. The correlation coefficient (r2) values >0.94, suggest that 
drug release mechanism from Didanosine tablets followed non-
Fickian (anomalous) transport mechanism. Kinetic results were 
given Table 5. 












FTIR: The FTIR spectra of pure Didanosine alone and its physical 
mixture with other excipients were carried out. Pure Didanosine 
displayed characteristic peaks at γ  (cm-1):  1820-1660 (-C=O strong 
absorption) 3400 (-CONH medium absorption) 1300-1000(-O- 
absorption) 3400(-OH – absorption). The FT-IR spectra of pure drug 
and drug + excipients are shown in Fig 4. The FTIR spectrum of 
Didanosine pure drug exhibited characteristic absorption at 3400 
cm−1 representing the presence of –CONH. Whereas a characteristic 
absorption band at 1820-1660 cm−1 is due to the presence of -C=O, 
and absorption band at 1300-1000. Similarly the IR spectrum of 
Didanosine and other polymers namely Xanthan gum, Guar gum and 
Karaya gum showed characteristic absorption bands for the 
functional groups -CONH, -N, COC and -OH at or near that of 
Didanosine absorption bands values indicating that there was no 
chemical and physical change in the functional groups present in 
Didanosine. 
DSC: The DSC of pure drug and formulations were shown in Fig 5. 
The DSC of pure drug was subjected to DSC which has shown a sharp 
melting point at 1790C. The DSC of formulation containing 
Didanosine and Xanthan gum shows a little range of melting process. 
Melting point at 184.00C. The DSC of formulation containing 
Didanosine and guar gum produced a warm melting point at 
184.60C. The DSC of the formulation containing Didanosine and 
Karaya gum produced a warm melting point at 185.60C in all the 
cases which leads to a physical mixture. Looking at the DSC date 
observed in all the case one can conclude that during the 
formulation with various excipients no chemical reaction takes place 
between drug and excipients during process. The melting point of 
product will be same range with negligible variation. That means it 
can be justified there is no interaction between drug and excipients. 
The stability studies of the optimized tablets WGX3, WGG5 and 
WGK9 were carried out according to ICH guidelines at 40±20C/ 75±5 
% RH for three months. After three month the tablets were again 
analyzed for the hardness, friability and drug content uniformity. No 
change was observed in the hardness, friability and disintegration 
time of tablets prepared by co-processed technique. No significant 
change was observed in all the formulations. The results were 
shown in Table 5.  
 
 
Fig 4: IR Spectra of Didanosine, Formulation with xanthan gum, 






Zero order  (r2) Higuchi model  (r2) Kors.-Peppas (r2) 
Kors.-Peppas 
(n) 
WGX1 0.929 0.975 0.963 0.946 0.645 
WGX2 0.884 0.974 0.959 0.958 0.592 
WGX3 0.865 0.978 0.977 0.990 0.677 
WGX4 0.915 0.975 0.964 0.965 0.595 
WGG5 0.814 0.981 0.976 0.990 0.682 
WGG6 0.958 0.975 0.979 0.991 0.682 
WGG7 0.926 0.993 0.941 0.981 0.777 
WGG8 0.845 0.944 0.856 0.902 0.738 
WGK9 0.759 0.986 0.941 0.960 0.699 
WGK10 0.840 0.985 0.934 0.955 0.712 






























Rao et al. 




Fig 5: DSC Thermograms of Didanosine, Formulation with xanthan gum, Formulation with guar gum and Formulation with karaya gum  












30 days 98.12 ± 0.14 6.16 ± 0.28 0.31 ± 0.10 
60 days 99.54 ± 0.41 5.76 ± 0.18 0.39 ± 0.11 
90 days 98.98 ± 0.11 6.14 ± 0.14 0.26 ± 0.02 
WGG5 
30 days 99.94 ± 0.12 6.03 ± 0.43 0.34 ± 0.02 
60 days 99.11 ± 0.10 6.07 ± 0.51 0.30 ± 0.07 
90 days 98.54 ± 0.24 6.03 ± 0.13 0.29 ± 0.01 
WGK9 
30 days 99.44 ± 0.14 5.97 ± 0.45 0.28 ± 0.11 
60 days 97.99 ± 0.19 6.03 ± 0.08 0.43 ± 0.17 
90 days 99.25 ± 0.20 6.13 ± 0.41 0.31 ± 0.04 
 
CONCLUSION 
The sustained release matrix tablets of Didanosine could be 
prepared using Xanthan gum, Guar gum and Karaya gum by wet 
granulation method. The prepared sustained release matrix tablets 
subjected to FTIR and DSC Study suggested that there was no drug-
polymer and polymer-polymer interaction. The matrix tablets 
showed good Swelling up to 6 hrs in phosphate buffer pH 7.4 
maintaining the integrity of formulation. The release of Didanosine 
was conducted for 8 hrs. The optimized formulations WGX3, WGG5 
and WGK9 sustained the release up to 8 hrs. Hence Didanosine along 
with Xanthan gum, Guar gum and Karaya Gum could be used to 
prepared sustained released matrix tablets. The release obeyed zero 
order kinetics with mechanism of release was erosion followed by 
non-fickian diffusion. Among all the formulations WGK9 is the best 
shows excellent release around 99% after 8 hrs. The prepared 
matrix tablets of Didanosine were stable. So, it may be concluded 
that sustained release matrix tablets would improve the patient 
compliance and bioavailability may be improved. 
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